港股午评：恒指半日涨1.07%重回27000点，黄金股持续走高，保险及银行股活跃

Market Overview - The Hong Kong stock index showed an upward trend in early trading on January 27, with the Hang Seng Index rising by 1.07% to 27,053.05 points, the Hang Seng Tech Index increasing by 0.2% to 5,737.27 points, and the China Enterprises Index up by 0.86% to 9,225.77 points [1] - Major technology stocks exhibited mixed performance, with Alibaba up by 2.18%, Tencent Holdings up by 1.08%, JD.com down by 1.38%, and Meituan down by 0.51% [1] - Gold stocks continued to rise, with Zijin Mining and Zijin Gold International reaching historical highs, while insurance stocks were active, with AIA Group rising over 3% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [3] - Vison Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing authorization application of injectable Long-acting Growth Hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization of BRIMOCHOL PF for presbyopia treatment in Singapore and Vietnam through partnerships with AFT and Qianshou [5] - Heng Rui Pharmaceutical (01276.HK) received a clinical trial approval notice for SHR-1049 injection [6] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by relevant bondholder meetings [7] - Aibo Technology Holdings (08279.HK) entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [8] - Future Data Group (08229.HK) signed a strategic cooperation framework agreement with Linghe Culture [9] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [10] Institutional Insights - According to招商国际, the Hong Kong stock market is currently in an earnings vacuum period, with high growth expectations for new economy sectors boosting market confidence. The appreciation of the RMB is favorable for Hong Kong stocks, and domestic policies are focusing on technological innovation and expanding domestic demand [11] - Citigroup believes that the outlook for Hong Kong stocks is better than that of A-shares, with optimism for 2026 supported by both southbound and foreign capital. However, potential risks include high overseas interest rates and corporate earnings falling short of expectations [11] - Huatai Securities noted that technology and cyclical "consumables" are expected to lead the recovery of Hong Kong stocks, with external pressures easing and domestic macro data stabilizing [11] - Guoyuan International suggests that the current environment may allow Hong Kong stocks to continue outperforming U.S. stocks, driven by low long-term valuation levels and potential recovery in domestic credit demand [12]